Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study Meeting Abstract
| Authors: | Möhler, M.; Janjigian, Y.; Al-Batran, S. E.; Wainberg, Z.; Van Cutsem, E.; Molena, D.; Muro, K.; Hyung, W. J.; Wyrwicz, L.; Oh, D. Y.; Omori, T.; Garrido, M.; Sousa, O. S. C.; Liberman, M.; Oliden, V. C.; Bilici, M.; Kurland, J. F.; Xynos, I.; Mann, H.; Tabernero, J. |
| Abstract Title: | Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study |
| Meeting Title: | 36. Deutscher Krebskongress - Fortschritt gemeinsam gestalten |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 47 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Feb 21-24 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2024-02-01 |
| Start Page: | 229 |
| Language: | English |
| ACCESSION: | WOS:001332646400569 |
| PROVIDER: | wos |
| DOI: | 10.1159/000535363 |
| Notes: | Meeting Abstract: 1000 -- 'The 36th German Cancer Congress - Building Progress Together' -- Located in the section 'Endocrine Tumors' (Late Breaking) -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
